Lilly brings Glucagon app to Android devices

Lilly brings Glucagon app to Android devices – PMLiVE

);
// ]]>

if (jQuery.cookie("cc_cookie_accept") == null)
$("#pm-structure,#header").css("margin-top","40px");
else

);

if (jQuery.cookie('cc_cookie_decline') == "cc_cookie_decline")
else

// ]]>

Follows app’s 2012 debut in iPhone version

Lilly has brought out its Glucagon mobile app in a version for Android devices, nearly three years after it first appeared for iPhones.  

The free app, for carers and healthcare providers, serves as a teaching tool and can help patients prepare for insulin coma treatment with Lilly Glucagon for Injection (rDNA origin) during a severe low blood sugar episode.

It offers an injection tutorial and emergency instructions, and a kit location log, so kits can be easily located during an emergency, and an expiration date log that sends a reminder when a kit is getting close to its expiration date, so a new kit can be obtained before this date.

Matt Caffrey, senior director of consumer marketing at Lilly Diabetes, said: “Lilly Diabetes is committed to developing personalised solutions to help people with diabetes achieve their treatment goals and improve their outcomes – including the creation of innovative online tools that provide a range of support.

“The new version of the Lilly Glucagon Mobile App leverages the power of Android mobile technology, helping us reach even more caregivers and providing another opportunity to support people living with type 1 diabetes.”

The company’s other diabetes-focused mobile apps include Lilly AudioTour for poster sessions at last month’s American Diabetes Association congress and the Trulicity Reminder app for UK patients taking its once-weekly GLP-1 agonist.

More recently the company took a stake in digital health firm Companion Medical, a San Diego-based company that’s working on a Bluetooth-enabled insulin pen and associated smartphone app.

Source PMLive http://www.pmlive.com/blogs/digital_intelligence/archive/2015/july/lilly_beings_glucagon_app_to_android_devices_789276

Lilly brings Glucagon app to Android devices

AstraZeneca forms 'smart inhaler' digital health partnership

AstraZeneca forms ‘smart inhaler’ digital health partnership

This follows a separate deal for a health coaching app for heart attack patients

Adherium’s Smartinhaler technology

AstraZeneca has formed a digital health partnership with Australian medical device company Adherium that will see the firms collaborate on the use of ‘smart inhalers’.

Adherium’s Smartinhaler electronic monitors record the time and date of inhaler use and then transmit the information to the patient’s mobile and their doctor.

The company said that AZ will use its device technology as the “pivotal component” within its global patient support programmes for patients with COPD and asthma.

AZ has already used Adherium’s technology in clinical trials, as well as piloting its use as a support tool to help patients manage their condition.

The pharma company will initially use the technology to monitor patients’ use of therapy and to provide personalised advice to patients based on their condition and medication use.

Future developments of the technology could see additional sensors added to it so assist with patient monitoring and, potentially, to assess a patient’s personalised risk factors.

Adherium said the deal was a world-first in its combination of digital health technology and blockbuster inhaler medications to improve health outcomes for patients with respiratory conditions.

Less than half of patients with asthma take their preventative medications as prescribed. In clinical trials the use of Adherium’s Smartinhaler has been show to increase adherence by up to 59% in adults and 180% in children with asthma.

Health coaching mobile app

The Adherium deal is AZ’s second digital health collaboration in a week, and follows hot on the heals of its tie-up with Vida on a live coaching app.

Their agreement will see the partners create a new app, called Day-By-Day, for patients who have had a heart attack.

Vida’s health coach app, which is generally used by those whose goal is weight-loss, usually costs $49 per month but AZ will cover the cost of eligible patients using the Day-By-Day app.

The app won’t be freely available to all, however. Instead it will be launched through a trial programme involving Duke University in North Carolina.

The Day-By-Day app may help AZ in its attempts to go ‘beyond the pill’, but it will be unbranded and has been designed to be used by patients, irrespective of which companies’ drugs they have been prescribed.

Source PMLive http://www.pmlive.com/blogs/digital_intelligence/archive/2015/july/astrazeneca_forms_smart_inhaler_digital_health_partnership_785567

AstraZeneca forms 'smart inhaler' digital health partnership